Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells

28 Dec 2020

Abstract excerpt

Hepatocellular carcinoma is one of the most common cancer types worldwide. In cases of advanced-stage disease, sorafenib is considered the treatment of choice. However, resistance to sorafenib remains a major obstacle for effective clinical application. Based on integrated phosphoproteomic and The Cancer Genome Atlas (TCGA) data, we identified a transcription factor, Y-box binding protein-1 (YB-1), with elevated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Hippo pathway signaling and YAP/TAZ
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33379356
DOI: 10.3390/ijms22010224

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma CellsPMID 33379356Read ↗

Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Targeting PCBP1 Sequentially Represses BAG1 and SOX2/β-catenin Axis to Inhibit HCC Cells Proliferation and Reverse Intrinsic Sorafenib ResistanceSemantic proximity Read ↗

Transcriptomic Profiling Identifies CSNK1E as a Key Mediator of Sorafenib Resistance in Hepatocellular CarcinomaSemantic proximity Read ↗

Comprehensive Network Analysis of the Molecular Mechanisms Associated with Sorafenib Resistance in Hepatocellular CarcinomaSemantic proximity Read ↗

Molecular Targeted Therapy for Hepatocellular Carcinoma: Present Status and Future DirectionsSemantic proximity Read ↗

TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.Semantic proximity Read ↗

Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinomaSemantic proximity Read ↗

YBX1 as a prognostic biomarker and potential therapeutic target in hepatocellular carcinoma: A comprehensive investigation through bioinformatics analysis and in vitro studySemantic proximity Read ↗

Phosphorylation of intestine-specific homeobox by ERK1 modulates oncogenic activity and sorafenib resistanceSemantic proximity Read ↗

Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCCSemantic proximity Read ↗

Ring Finger Protein 141 (RNF141) Mediates Resistance to Sorafenib in Hepatocellular Carcinoma and Its MechanismsSemantic proximity Read ↗

Inhibiting CBX4 efficiently suppress YAP nucleus translocation in hepatocellular carcinoma cells to protect against sorafenib resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.